Q3 2024 · 13F-HR
Decheng Capital LLCholdings as filed
Filed 2024-11-15 · accession 0001104659-24-119361
$422.2M
Reported value
26
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $206.7M | 49.0% | 5,478,810 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $59.4M | 14.1% | 25,954,439 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $22.6M | 5.35% | 1,250,000 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc | $13.3M | 3.15% | 869,790 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $13.1M | 3.09% | 71,772 | Common | SOLE |
| 452327109 | ILMN | Illumnia, Inc. | $12.4M | 2.93% | 94,767 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc. | $11.4M | 2.71% | 3,108,095 | Common | SOLE |
| G10830100 | BYSI | BeyondSpring Inc. | $11.4M | 2.69% | 4,958,143 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $9.8M | 2.32% | 590,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $9.4M | 2.24% | 189,098 | Common | SOLE |
| G4444C102 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $8.4M | 1.99% | 166,600 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $8.1M | 1.91% | 157,958 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $5.3M | 1.25% | 108,558 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $5.0M | 1.18% | 94,043 | Common | SOLE |
| 05153U107 | AURA | Aura Biosciences, Inc. | $4.6M | 1.09% | 515,555 | Common | SOLE |
| 81663L200 | WGS | GeneDx Holdings Corp. | $4.4M | 1.04% | 103,604 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $4.3M | 1.02% | 397,835 | Common | SOLE |
| 29446K106 | EQ | Equillium Inc. | $3.7M | 0.88% | 4,447,308 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $3.1M | 0.73% | 69,767 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $1.9M | 0.44% | 56,350 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $1.8M | 0.42% | 21,177 | Common | SOLE |
| 747324101 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $1.2M | 0.28% | 326,810 | Common | SOLE |
| 04963C209 | ATRC | AtriCure Inc. | $751,388 | 0.18% | 26,797 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $133,252 | 0.03% | 9,684 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC(NSM) | $90,700 | 0.02% | 2,000 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc. | $63,249 | 0.01% | 646,057 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.